Coronavirus (COVID-19) updates, visitor restrictions and resources →
Now offering telemedicine through our Virtual Visit online program for primary care and specialty care visits → Virtual Visit appointments are available for new and existing UF Health patients. Check the FAQ section and Request an Appointment section below for more information.

Call (904) 383-1052 to make an appointment or call your physician’s office if you have questions specific to your health needs.

Clinical Trial Details

A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome –the AEGIS-II Study
Study Description

The purpose of this study is to find out how effective and safe CSL112 is at reducing the risk of dying from heart related events, having another heart attack, or having a stroke.

If you agree to join the study, screening tests will be performed while you are in the hospital to assess your eligibility for the study. If you are eligible to take part in the study, you will be randomized to receive either the study drug or placebo. “Randomized” means that you will be assigned by chance, like flipping a coin, to take the study drug (CSL112) or the placebo. You will have a 50/50 chance of receiving either CSL112 or placebo.

Open Enrollment
Contact Name: Andrea Goosen
Contact Phone: (904) 244-5617
Contact Email:

Principal Investigator
Dominick J. Angiolillo, M.D., Ph.D., FACC